Resmed Acquires VirtuOx
Resmed (NYSE: RMD) has acquired VirtuOx, a leading independent diagnostic testing facility for sleep, respiratory, and cardiac conditions. VirtuOx's virtual testing platform provides at-home diagnostic services, helping reduce barriers to diagnosis with fast, flexible, and affordable options. The acquisition aims to streamline the diagnostic process, accelerate time between evaluation and treatment, and expand access to care for patients with sleep-disordered breathing and related conditions.
VirtuOx will operate as a fully owned subsidiary of Resmed, maintaining its existing brand and leadership team. The acquisition strengthens Resmed's virtual care capabilities, enhances its digital ecosystem, and deepens relationships with healthcare providers. Financial terms were not disclosed as the acquisition is not considered material to Resmed's financial results.
Resmed (NYSE: RMD) ha acquisito VirtuOx, una struttura indipendente leader nei test diagnostici per disturbi del sonno, respiratori e cardiaci. La piattaforma di test virtuali di VirtuOx offre servizi diagnostici a domicilio, contribuendo a ridurre le barriere alla diagnosi con opzioni rapide, flessibili e accessibili. L'acquisizione mira a semplificare il processo diagnostico, accelerare i tempi tra valutazione e trattamento, e ampliare l'accesso alle cure per pazienti con disturbi respiratori del sonno e condizioni correlate.
VirtuOx opererà come una controllata interamente posseduta da Resmed, mantenendo il proprio marchio e il team di leadership attuali. L'acquisizione rafforza le capacità di assistenza virtuale di Resmed, potenzia il suo ecosistema digitale e approfondisce i rapporti con i fornitori di servizi sanitari. I termini finanziari non sono stati divulgati poiché l'acquisizione non è considerata rilevante per i risultati finanziari di Resmed.
Resmed (NYSE: RMD) ha adquirido a VirtuOx, una instalación independiente líder en pruebas diagnósticas para trastornos del sueño, respiratorios y cardíacos. La plataforma de pruebas virtuales de VirtuOx ofrece servicios diagnósticos a domicilio, ayudando a reducir las barreras para el diagnóstico con opciones rápidas, flexibles y asequibles. La adquisición tiene como objetivo simplificar el proceso diagnóstico, acelerar el tiempo entre la evaluación y el tratamiento, y ampliar el acceso a la atención para pacientes con trastornos respiratorios del sueño y condiciones relacionadas.
VirtuOx operará como una subsidiaria de propiedad total de Resmed, manteniendo su marca y equipo de liderazgo actuales. La adquisición fortalece las capacidades de atención virtual de Resmed, mejora su ecosistema digital y profundiza las relaciones con los proveedores de atención médica. No se divulgaron los términos financieros ya que la adquisición no se considera material para los resultados financieros de Resmed.
Resmed (NYSE: RMD)는 수면, 호흡기 및 심장 질환에 대한 독립 진단 검사 시설인 VirtuOx를 인수했습니다. VirtuOx의 가상 검사 플랫폼은 가정에서 진단 서비스를 제공하여 빠르고 유연하며 저렴한 옵션으로 진단 장벽을 낮추는 데 도움을 줍니다. 이번 인수는 진단 과정을 간소화하고 평가에서 치료까지의 시간을 단축하며 수면 호흡 장애 및 관련 질환 환자에 대한 치료 접근성을 확대하는 것을 목표로 합니다.
VirtuOx는 기존 브랜드와 리더십 팀을 유지하며 Resmed의 완전 자회사로 운영됩니다. 이번 인수는 Resmed의 가상 진료 역량을 강화하고 디지털 생태계를 향상시키며 의료 제공자와의 관계를 심화합니다. 재무 조건은 공개되지 않았으며, 이번 인수는 Resmed의 재무 실적에 중대한 영향을 미치지 않는 것으로 간주됩니다.
Resmed (NYSE: RMD) a acquis VirtuOx, un centre de diagnostic indépendant de premier plan pour les troubles du sommeil, respiratoires et cardiaques. La plateforme de tests virtuels de VirtuOx propose des services de diagnostic à domicile, contribuant à réduire les obstacles au diagnostic grâce à des options rapides, flexibles et abordables. Cette acquisition vise à simplifier le processus de diagnostic, accélérer le délai entre l'évaluation et le traitement, et élargir l'accès aux soins pour les patients souffrant de troubles respiratoires liés au sommeil et de conditions associées.
VirtuOx fonctionnera comme une filiale entièrement détenue par Resmed, en conservant sa marque et son équipe de direction actuelles. L'acquisition renforce les capacités de soins virtuels de Resmed, améliore son écosystème numérique et approfondit les relations avec les prestataires de soins de santé. Les termes financiers n'ont pas été divulgués car l'acquisition n'est pas considérée comme significative pour les résultats financiers de Resmed.
Resmed (NYSE: RMD) hat VirtuOx übernommen, eine führende unabhängige Einrichtung für diagnostische Tests bei Schlaf-, Atemwegs- und Herz-Kreislauf-Erkrankungen. Die virtuelle Testplattform von VirtuOx bietet diagnostische Dienstleistungen für zu Hause an und hilft, Barrieren bei der Diagnose durch schnelle, flexible und erschwingliche Optionen zu verringern. Die Übernahme zielt darauf ab, den Diagnoseprozess zu optimieren, die Zeit zwischen Bewertung und Behandlung zu verkürzen und den Zugang zur Versorgung für Patienten mit schlafbezogenen Atemstörungen und verwandten Erkrankungen zu erweitern.
VirtuOx wird als vollständig im Besitz von Resmed befindliche Tochtergesellschaft betrieben und behält seine bestehende Marke sowie das Führungsteam bei. Die Übernahme stärkt Resmeds Fähigkeiten im Bereich der virtuellen Versorgung, verbessert das digitale Ökosystem und vertieft die Beziehungen zu Gesundheitsdienstleistern. Finanzielle Details wurden nicht bekannt gegeben, da die Übernahme für Resmeds Finanzergebnisse als nicht wesentlich angesehen wird.
- Expands Resmed's diagnostic capabilities through VirtuOx's virtual testing platform
- Accelerates time between evaluation and treatment for sleep apnea patients
- Strengthens partnerships with healthcare providers and home medical equipment providers
- Creates opportunities for expansion into adjacent areas like insomnia
- Retention of VirtuOx's existing leadership team ensures operational continuity
- Financial terms not disclosed, limiting investor ability to assess deal value
- Integration costs and potential operational challenges during merger
- May take time to realize synergies and growth opportunities
Insights
Resmed's acquisition of VirtuOx enhances patient journey by integrating diagnostics with treatment, addressing critical care pathway bottlenecks in sleep medicine.
Resmed's strategic acquisition of VirtuOx represents a significant vertical integration move that addresses a critical bottleneck in sleep medicine: the diagnosis phase. By acquiring these at-home diagnostic capabilities, Resmed can now influence the patient journey from initial testing through ongoing treatment – potentially reducing the substantial drop-off that occurs between suspicion of sleep apnea and actual therapy initiation.
This acquisition aligns perfectly with broader healthcare's shift toward virtualization and home-based care delivery. The traditional sleep diagnosis pathway often requires inconvenient in-lab testing, creating friction that leaves millions of sleep apnea cases undiagnosed. VirtuOx's virtual platform removes these barriers with faster, more flexible diagnostic options that can expand the top of Resmed's patient funnel.
While described as non-material financially, the strategic value is substantial. By controlling both diagnostic and treatment phases, Resmed creates a more seamless patient experience, potentially improving therapy adherence rates – a persistent challenge in sleep medicine. The decision to maintain VirtuOx as a separate subsidiary with its leadership intact suggests Resmed recognizes the value in preserving their specialized operational model.
The mention of expansion into adjacent areas like insomnia indicates Resmed is positioning itself beyond its core sleep-disordered breathing focus toward broader sleep health management, potentially enlarging their addressable market. For healthcare providers and equipment suppliers, this integration could streamline workflows through more connected digital tools, reinforcing Resmed's ecosystem strategy.
Acquisition extends Resmed's reach earlier in patient care pathway, strengthening its ecosystem while addressing underdiagnosis in sleep disorders.
This acquisition marks an important evolution in Resmed's business model from focused device manufacturer toward comprehensive sleep and respiratory health solution provider. By acquiring VirtuOx's independent diagnostic testing capabilities, Resmed strategically addresses one of the biggest challenges in sleep medicine – the significant underdiagnosis of conditions like obstructive sleep apnea.
The sleep diagnostics market has been shifting from traditional in-lab polysomnography toward home sleep testing for years, a trend accelerated by broader healthcare virtualization. Bringing these capabilities in-house allows Resmed to influence the patient journey earlier, potentially capturing more patients for its core CPAP and respiratory devices while reducing the all-too-common patient drop-off between diagnosis and treatment initiation.
Keeping VirtuOx as a separate subsidiary with its leadership team intact signifies Resmed's recognition that diagnostic services operate differently from their traditional device business. This approach typically works well when integrating service-oriented businesses that benefit from operational independence while leveraging parent company resources.
The press release mentions "not material to Resmed's financial results," suggesting VirtuOx's current revenue contribution is modest relative to Resmed's
The referenced expansion into adjacent areas like insomnia suggests this acquisition may support Resmed's diversification beyond its core sleep apnea focus, potentially opening new growth avenues as the company continues its transformation into a comprehensive sleep and respiratory health leader.
Acquisition supports Resmed’s growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions.
The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx’s at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected way.
VirtuOx’s virtual testing platform helps reduce barriers to diagnosis, offering fast, flexible, and affordable options for patients—particularly those with sleep-disordered breathing or other conditions that are often underdiagnosed. For people suspected of having obstructive sleep apnea (OSA), a more streamlined, digital-first experience can make the difference between following through on testing and treatment—or falling out of the care pathway entirely.
“This is about creating a simpler, more connected pathway to care,” said Justin Leong, Chief Product Officer at Resmed. “By integrating VirtuOx’s diagnostic capabilities into our ecosystem, we can help accelerate the time between evaluation and treatment, reduce drop-off, and help more people access the life-changing benefits of therapy for sleep apnea and related conditions.”
This acquisition strengthens Resmed’s ability to partner with healthcare providers to help streamline the diagnostic process and alleviate current bottlenecks, while expanding collaboration with home medical equipment providers to efficiently and expeditiously support patients to start treatment. It further enhances the company’s ability to serve healthcare providers with integrated tools that improve care coordination, patient engagement, and outcomes.
“VirtuOx and Resmed are aligned in our focus to simplify healthcare and expand access,” said Steve Lica, CEO of VirtuOx. “Joining Resmed gives us the opportunity to scale our impact, reach and help more patients, and keep innovating on behalf of the providers and health systems we serve.”
The acquisition supports a growing demand for home-based care—driven by increased awareness, convenience, and digital innovation. It also creates opportunities to expand into adjacent areas such as insomnia, while deepening Resmed’s relationships with physicians, sleep labs, and home medical equipment providers.
VirtuOx will operate as a fully owned subsidiary of Resmed following the transaction, continuing to serve partners and patients under its existing brand in the near term. The VirtuOx leadership team will remain in place and continue to drive the company’s growth and innovation strategy.
Financial terms are not being disclosed, as the acquisition is not material to Resmed’s financial results.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
About VirtuOx
VirtuOx is a software-enabled independent diagnostic testing facility and provider of technology solutions to facilitate in-home and remote testing services for sleep, respiratory, cardiac, and other health conditions across the United States.
For Media:
Kristen Handley Slater, Resmed
news@resmed.com
For Investors:
Mike Ott or Wendy Wilson, Resmed
Investorrelations@resmed.com
FAQ
What company did Resmed (RMD) acquire in May 2025?
How will VirtuOx operate after being acquired by Resmed?
What are the financial terms of Resmed's acquisition of VirtuOx?
How will the VirtuOx acquisition benefit Resmed's business?
What services does VirtuOx provide to Resmed's target market?
